KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $28.3 million.

  • Castle Biosciences' Capital Expenditures rose 132.58% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.4 million, marking a year-over-year increase of 48.27%. This contributed to the annual value of $28.3 million for FY2024, which is 107.96% up from last year.
  • As of FY2024, Castle Biosciences' Capital Expenditures stood at $28.3 million, which was up 107.96% from $13.6 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Capital Expenditures peaked at $28.3 million during FY2024, and registered a low of $3.5 million during FY2021.
  • Moreover, its 3-year median value for Capital Expenditures was $13.6 million (2023), whereas its average is $15.9 million.
  • As far as peak fluctuations go, Castle Biosciences' Capital Expenditures spiked by 407.04% in 2020, and later dropped by 26.69% in 2021.
  • Over the past 5 years, Castle Biosciences' Capital Expenditures (Yearly) stood at $4.8 million in 2020, then fell by 26.69% to $3.5 million in 2021, then spiked by 61.70% to $5.6 million in 2022, then soared by 141.85% to $13.6 million in 2023, then skyrocketed by 107.96% to $28.3 million in 2024.